Trial Profile
A Phase 1 Dose Escalation Study of TTI-237 Administered Intravenously Every 3 Weeks in Subjects With Advanced Malignant Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 19 Feb 2009
Price :
$35
*
At a glance
- Drugs Cevipabulin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 09 Sep 2005 New trial record.